Dolby Laboratories (DLB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

CervoMed (CRVO) provided an update on its neflamapimod development program in dementia with Lewy bodies, DLB, as part of an oral presentation ...

Q1 2025 Earnings Call Transcript January 29, 2025 Dolby Laboratories, Inc. beats earnings expectations. Reported EPS is $1.14, expectations were $1.07. Operator: Ladies and gentlemen, thank you for ...

Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently ma ...

The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus ...

Dolby Laboratories Inc (DLB) reports a 13% revenue increase, fueled by robust licensing performance and expanding automotive ...

In a report released yesterday, Steve Frankel from Rosenblatt Securities reiterated a Buy rating on Dolby Laboratories (DLB – Research Report), ...

Dolby Laboratories (NYSE:DLB) reported its financial results for the first quarter of 2025, surpassing earnings expectations ...

Here's a brief overview of the earnings report. Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up $41.42 million from the same ...

Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up ...

Dolby Laboratories (NYSE:DLB – Get Free Report) will likely be posting its quarterly earnings results after the market closes ...